trial summary · NCT07578077
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Mantle Cell Lymphoma, sponsored by City of Hope Medical Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase I/II trial tests the safety, side effects, best dose and effectiveness of golcadomide in combination with rituximab in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Golcadomide may help block the formation, growth or spread of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving golcadomide in combination with rituximab may better treat patients with relapsed or refractory mantle cell lymphoma.
Source record: https://clinicaltrials.gov/study/NCT07578077
Facts
| registry id | NCT07578077 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Recurrent Mantle Cell Lymphoma |
| sponsor | City of Hope Medical Center |
| sponsor class | OTHER |
| enrollment | 58 |
| start date | 2026-12-21 |
| primary completion | 2030-04-21 |
| completion | 2030-04-21 |
| results posted | not reported |
Conditions
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
Interventions
- Biopsy Procedure
- Biospecimen Collection
- Bone Marrow Biopsy
- Computed Tomography
- Golcadomide
- Positron Emission Tomography
- Rituximab
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.